Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
- Authors: Goncharenko ON1, Ametov AS1, Isakova MR1
-
Affiliations:
- ГОУ ДПО "Российская медицинская академия последипломного образования" Минздравсоцразвития России, Москва
- Issue: Vol 84, No 8 (2012)
- Pages: 67-71
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31101
- ID: 31101
Cite item
Full Text
Abstract
Aim. To evaluate the efficiency and safety of early combination therapy with sulfonylurea derivatives (SUD) and insulin sensitizers in patients with type 2 diabetes mellitus (T2DM). Subjects and methods. Forty patients (31 women and 9 men; mean age 57.7±0.9 years) with decompensated T2DM (НbА1с 8.16±0.27%), a mean body mass index of 32.7±0.7 kg/m2, who received glimepiride, were examined. The duration of T2DM was 3.3±0.4 years. The patients had concomitant cardiovascular diseases (CVD). Coronary heart disease and hypertensive disease (HD) were treated; the doses of the agents were not adjusted during the study. For T2DM compensation, all the patients were given insulin sensitizers (rosiglitazone 4 mg) in addition to glimepiride. The treatment lasted 24 weeks. Carbohydrate and lipid metabolic parameters, insulin resistance, body weight, structural and functional parameters, and heart rate were estimated before and after the treatment. Results. During the combination therapy, there were decreases in the level of НbА1с from 8.16±0.27 to 6.84±0.15%, fasting blood glucose from 8.89±0.35 to 6.77±0.16 mmol/l, postprandial blood glucose from 8.66±0.24 to 7.761±0.20 mmol/l, HOMA index from 5.88±0.70 to 3.75±0.44. The rate of hypoglycemic reaction reduced. Sugar-lowering therapy was observed to have, on average, a positive impact on blood lipid composition and cardiovascular parameters in the group. Echocardiography (EchoCG) identified a group of patients with negative cardiac structural and functional changes. Conclusion. The combination therapy with SUD and insulin sensitizers was stated to be effective in maintaining the reached blood glucose level, reducing the risk of hypoglycemic reactions, and positively affecting lipid metabolism. The therapy resulted in cardiovascular improvement only in patients without obvious signs of CVD while it caused negative EchoCG changes (transformation of concentric to eccentric left ventricular hypertrophy) in patients with a long-term (more than 7 years) history of HD and pronounced cardiac structural and functional alterations.
Full Text
##article.viewOnOriginalSite##About the authors
O N Goncharenko
ГОУ ДПО "Российская медицинская академия последипломного образования" Минздравсоцразвития России, Москва
Email: viola23march@mail.ru
A S Ametov
M R Isakova
Email: maryana78@yandex.ru
References
- Соколов Е.И. Диабетическое сердце. М: Медицина 2002: 322-335.
- Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. Руководство для врачей. М 2006.
- Aракелянц А.А., Горохова С.Г. Поражение сердца при сахарном диабете. Росс кардиол журн 2004; 1: 80-86.
- Мычка В.Б., Чазова И.Е. Сердечно-сосудистые осложнения сахарного диабета типа 2. Consilium Medicum 2003; 5: 9: 504-509.
- Палеев Н.Р., Калинин А.П., Мравян С.Р. Сахарный диабет и сердце. Клин мед 2005; 8: 37-42.
- Аметов А.С. Избранные лекции по эндокринологии. М: Медицинское информационное агентство 2009.
- Аметов А.С. Сахарный диабет 2-го типа. Основы патогенеза и терапии. Учебное пособие. М: Медицина 2003: 7-62.
- Аметов А.С. Инсулиносекреция и инсулинорезистентность: две стороны одной медали. Пробл эндокринол 2002; 3: 31-36.
- Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
- Смирнова О.М. Принципы терапии впервые выявленного сахарного диабета 2-го типа. Место Амарила (глимепирида): свойства, эффективность, безопасность. Сахарный диабет 2009; 1: 1-4.
- Анциферов М.Б., Дорофеева Л.Г. Авандия (росиглитазон) - современный инсулиновый сенситайзер для коррекции инсулинорезистентности при сахарном диабете типа 2. Фарматека 2005; 12: 16-23.
- Diamant M., Heine R.J. Thiazolidindionediones in type2 diabetes mellitus: current clinical evidence. Drugs 2003; 63: 1373-1405.
- Kahn S.E., Haffner S.M., Heise M.A. et al. ADOPT Study Group. Glycemik durability of rosiglitazone, metformin, or gliburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
- Алексеева О.П., Шаленкова М.А. Стабильная стенокардия: современные подходы к диагностике и лечению. Учебное пособие. Н. Новгород; 2005.
- Чазов Е.И., Кухарчук В.В., Бойцов С.А. Руководство по атеросклерозу и ишемической болезни сердца. М: Media Medica 2007.
- Robertson R.P., Harmon J., Tran P.O.T., Poitout V.B. Cell glucose toxicity, lipotoxiciti, and chronic oxidative stress in type 2 diabetes. Diabetes 2004; 53: Suppl 1: 119-124.
![](/img/style/loading.gif)